• Sofoklis Mitsos, Alexandros Stamatopoulos, Davide Patrini, Robert S George, David R Lawrence, and Nikolaos Panagiotopoulos.
• University College London Hospitals, NHS Foundation Trust, 16-18 Westmoreland Street, W1G 8PH London, United Kingdom. sophocmit@yahoo.gr.
• Adv Respir Med. 2018 Jan 1; 86 (1): 36-43.

IntroductionCastleman's disease is a rare benign lymphoproliferative disorder of unknown etiology. The disease occurs in two clinical forms with different prognoses, treatments and symptoms: a unicentric form (UCD), which is solitary, localized, and a multicentric form characterized by generalized lymphadenopathy and systemic symptoms. This article aims to review the current literature to consolidate the evidence surrounding the curative potential of surgical treatment to the unicentric type.Material And MethodsA systematic review of English-language literature was performed and databases (Medline, Pubmed, the Cochrane Database and grey literature) were searched to identify articles pertaining to the treatment of unicentric form of Castleman's disease. Each article was critiqued by two authors using a structured appraisal tool, and stratified according to the level of evidence.ResultsAfter application of inclusion criteria, 14 studies were included. There were no prospective randomized control studies identified. One meta-analysis including 278 patients with UCD reported that resective surgery is safe and should be considered the gold standard for treatment. Seven retrospective studies enhance this standpoint. Radiotherapy (RT) has been used in six studies with controversial results.ConclusionsWe conclude that surgical resection appears to be the most effective treatment for Unicentric Castleman's Disease of the thoracic cavity. Radiotherapy can also achieve clinical response and cure in selected patients.

14 keywords...

hide…